Our commitment to achieve the best possible results for every dialysis patient has fuelled our passion for haemodiafiltration (HDF). This passion rests on the firm belief that HDF is the best therapy for every patient.
Our conviction in HDF is now widely shared across the scientific community and backed by evidence. In recent years several studies have already confirmed the benefits of HDF1,2,3,4. The latest, the Catalonian high-volume HDF study1, proves the benefits of this therapy beyond doubt. Convincing scientific evidence for significantly improved patient outcomes combined with the simple and safe use of the 5008 CorDiax are compelling reasons to switch to HighVolumeHDF® – now.
That’s why for more than 30 years Fresenius Medical Care has been developing products for Cardioprotective Haemodialysis, leading to the CorDiax product line — which perfectly supports the application of HighVolumeHDF® therapy.
1 Maduell F. et al., J Am Soc Nephrol (2013); 24: 487-497.
2 Ok E. et al., Nephrol Dial Transplant (2013); 28(1): 192-202.
3 Grooteman M.P. et al., J Am Soc Nephrol (2012); 23(6): 1087-96.
4 Canaud B. et al., Kidney Int (2006); 69(11): 2087-93.
“Conventional HDF with solution bags"
1988: A2008 Online HDF
„Our first system for online preparation of substitution fluid”
1998: 4008H ONLINEplus
„Advanced ONLINEplus technology as optional modul”
2005: 5008 Therapy System
“Online haemodiafiltration as standard treatment mode“
2012: 5008 CorDiax & 5008S CorDiax
“With AutoSub plus HighVolumeHDF® becomes as simple and safe as HD”
HDF with its numerous positive effects on dialysis-relatedcardiovascular risk factors is currently acknowledged as the most effectivedialysis treatment modality, combining both – diffusion and convection.